Clinical trials: Growth
ADHD, Growth
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
Previous NIH funded Attention Deficit Hyperactivity Disorder (ADHD) trials in children found that daily stimulant therapy produced sustained growth deficits.
- Trial name
- NCT01109849
- Testing
- behavior therapy, Extended release (ER) methylphenidate product, monitoring
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Florida International University
Celiac Disease in Children
Entities and Variables Related to Catch-up Growth
A retrospective monocentric observational no-profit study with the aim of evaluating the entity and potential variables influencing the catch-up growth of childhood gluten-free diet patients with celiac disease during a 10-year…
- Trial name
- NCT06364735
- Where
- Italy
- Volunteers
- 900 people
- Sponsor
- ASST Fatebenefratelli Sacco
Children, Haemodialysis
Haemodiafiltration vs Conventional Haemodialysis in Children
Children on conventional haemodialysis (HD) die of heart disease. Also, they can be malnourished and short. Haemodiafiltration (HDF) is a newer type of dialysis that achieves better removal of toxins and excess fluid than HD.
- Conditions
- Children, Haemodialysis, Haemodiafiltration
- Trial name
- 3H (NCT02063776)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Cow Milk Allergy
A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy
This study involves the use of 2 different Neocate formulas: a control formula called Neocate Infant and a test Neocate formula.
- Trial name
- CMA (NCT00664768)
- Testing
- Neocate Infant, new Neocate
- Where
- 22 sites in United States
- Volunteers
- 126 people
- Sponsor
- Nutricia North America
Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
- Trial name
- NCT03648814
- Testing
- Intracameral injection, Intravitreal injection
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Prince of Songkla University
Central Retinal Vein Occlusion
Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
Recent studies have shown a remarkably positive effect of 6 monthly injections of Ranibizumab on eyes with CRVO. The disease may cause severe sight threatening complications, partly due to restrictions in blood flow and…
- Trial name
- LuRVO (NCT01360385)
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
Other Disorders of Bone Development and Growth
Assessing the Impact of Contraceptives on Bone Health Using 41Ca
This preclinical randomized crossover study will examine the effects of oral versus non-oral contraceptive therapy on bone turnover in young exercising women.
- Trial name
- NCT02367846
- Testing
- Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Penn State University
Hypoglycemia, Infant, Small for Gestational Age
Dextrose Gel Does Not Prevent Neonatal Hypoglycemia
This was a quasi-experimental pilot study comparing blood glucose values 30 minutes after feeding alone or feeding + dextrose gel in newborns at risk for transient neonatal hypoglycemia.
- Conditions
- Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia
- Trial name
- NCT02523222
- Testing
- 40% Dextrose gel
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Baylor College of Medicine
Breast Cancer
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
This study will evaluate the effect of bevacizumab in combination with chemotherapy or endocrine therapy, as preoperative treatment, in participants with HER2 negative breast cancer.
- Trial name
- NCT00773695
- Testing
- Aromatase Inhibitor, Bevacizumab, Epirubicine
- Where
- 3 sites in Norway
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Anorexia Nervosa, Osteopenia
Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa
Decreased bone strength is a serious medical problem present in many women with Anorexia Nervosa, or disordered eating. Women with weaker bones are more likely to suffer broken bones than women with normal bone strength.
- Conditions
- Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
- Trial name
- NCT00283595
- Testing
- Recombinant Human Growth Hormone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Congenital Heart Disease
Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
This is a Phase III randomized controlled trial of a passive ROM exercise program that will be performed in infants with HLHS and other single right ventricle anomalies following the Norwood procedure at PHN and Auxiliary Centers.
- Trial name
- T4G RCT (NCT04702373)
- Testing
- passive range of motion exercise therapy
- Where
- 10 sites in United States, Canada
- Volunteers
- 144 people
- Sponsor
- Carelon Research
Non-small Cell Lung Cancer
Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
Study hypothesis is that aprepitant is more effective than desloratadine in relieving pruritus caused by EGFR TKIs. Primary endpoint is the effective rate of pruritus, effective treatment defined as visual analogue scale (VAS)…
- Trial name
- EGFR-TKIs (NCT02646020)
- Testing
- Aprepitant, Desloratadine
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Penile Squamous Cell Carcinoma (PSCC)
Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma
Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease. Supportive evidence for the value of systemic therapy does not exist for this disease and there are no agents currently approved by…
- Trial name
- NCT02541903
- Testing
- Gilotrif
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Alabama at Birmingham
Intrauterine Growth Restriction, Preterm Birth
Respiratory Morbidity of Late-Preterm Vs Intrauterine Growth Retarded Infants at School Age
Background: It is increasingly recognized that late preterm infants have increased respiratory morbidity in the neonatal period as well as decreased lung function in later life.
- Trial name
- NCT04849494
- Testing
- ATS-DLD-78-C and ISAAC questionnaires
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Marmara University
Optic Pathway Glioma
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
Infantile optic pathway glioma (OPG) is generally benign and slow-growing, but due to infiltration and compression of sensitive neuronal structures in the optical pathways, progressive visual loss is a frequent and highly…
- Trial name
- NGF-OPG (NCT05733572)
- Testing
- CHF6467
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Benedetto Falsini
Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer
This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor…
- Trial name
- NCT06686602
- Testing
- No drug
- Where
- United States
- Volunteers
- 13,759 people
- Sponsor
- Daiichi Sankyo
Respiratory Distress Syndrome, Transient Tachypnea of Newborn
The Possible Effect Of Amniotic Fluid pH On Neonatal Morbidities In Maternal Inflammation/Infection Associated Pregnancies
Amniotic fluid (AF) pH can be affected by the maternal and/or fetal conditions such as PPROM, prematurity or fetal distress. It is known that fetal urine is the major content of AF since 20th gestational week.
- Conditions
- Respiratory Distress Syndrome, Transient Tachypnea of Newborn, Intrauterine Growth Retardation
- Trial name
- NCT02691559
- Testing
- Amniotic fluid analysis by blood gas device
- Where
- Turkey (Türkiye)
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities…
- Trial name
- NCT01449461
- Testing
- Brigatinib
- Volunteers
- 137 people
- Sponsor
- Ariad Pharmaceuticals